EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
On August 11, 2025, the European Food Safety Authority (EFSA) announced its expert panel has found no safety concerns for Vitamin E polyethylene glycol succinate (TPGS) as a food additive at proposed use levels. The Food Additives and Flavourings (FAF) panel concluded that Vitamin E TPGS can be safely used as an emulsifier in various food categories.
Scientific evaluation showed that TPGS is mostly monoesters (over 82%) and less than 20% diesters, with the ester bond proving stable under testing conditions. The additive is poorly absorbed and does not serve as a vitamin E source for healthy individuals. No genotoxicity or negative effects on reproduction and development were seen at doses up to 1000 mg/kg body weight per day, the highest tested.
Given the available data, the panel employed a margin of exposure (MOE) approach and determined the calculated values were sufficient to assure safety. The EFSA’s conclusion clears the way for Vitamin E TPGS to be used in foods at the proposed levels without safety concerns.
Looking for chemical products? Let suppliers reach out to you!
2026-06-29
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
Recommend Reading
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Cyclohexane Market Faces Insufficient Demand, Prices Remain Stable
-
This Week Aniline Market Stabilizes and Rises (11.3-11.7) in China
-
Cost Pressures Mount as PC Market Weakens in Mid-November
-
China's urea market shows a strong upward trend (11.3-11.7)
-
“The Agency Revolution”: BASF Breaks Into Dongfeng Liuzhou’s Supply Chain